Lactobacillus rhamnosus probiotic treatment modulates gut and liver inflammatory pathways in a hepatocellular carcinoma murine model. A preliminary study.
Food Chem Toxicol
; 183: 114314, 2024 Jan.
Article
en En
| MEDLINE
| ID: mdl-38052407
ABSTRACT
BACKGROUND AND AIMS:
Hepatocellular carcinoma (HCC) is a growing global concern with an increasing incidence rate. The intestinal microbiota has been identified as a potential culprit in modulating the effects of antitumoral drugs. We aimed to assess the impact of adding Lactobacillus rhamnosus probiotic to regorafenib in mice with HCC.METHODS:
Cirrhosis and HCCs were induced in 56 male Swiss mice via diethylnitrosamine injection and carbon tetrachloride administration. Mice were divided into four groups treated with vehicle (VC), regorafenib (Rego), L. rhamnosus probiotic, and a combination of regorafenib and probiotic (Rego-Pro). After 3 weeks of treatment, liver and intestinal fragments were collected for analysis.RESULTS:
Regorafenib elevated gut permeability, an effect mitigated by probiotic intervention, which exhibited a notable correlation with reduced inflammation (p < 0.01). iNOS levels were also reduced by adding the probiotic with respect to the mice treated with regorafenib only (p < 0.001). Notably, regorafenib substantially increased IL-6, TNF-a and TLR4 in intestinal fragments (p < 0.01). The administration of the probiotic effectively restored IL-6 to its initial levels (p < 0.001).CONCLUSION:
Reducing systemic and intestinal inflammation by administering L. rhamnosus probiotic may alleviate tumoral resistance and systemic adverse effects.Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Carcinoma Hepatocelular
/
Probióticos
/
Lacticaseibacillus rhamnosus
/
Hepatitis
/
Neoplasias Hepáticas
Idioma:
En
Revista:
Food Chem Toxicol
Año:
2024
Tipo del documento:
Article